Warrant Agreement Dated as of August 13, 2001 WARRANT AGREEMENT, dated as of August 13, 2001, between BioTime, Inc., a California corporation (the "Company"), and the persons named on Exhibit A (the "Lenders"). The Company proposes to issue Common...Warrant Agreement • August 14th, 2001 • Biotime Inc • Biological products, (no disgnostic substances) • California
EXHIBIT 4.4 Warrant Agreement Dated as of ________ , 2003 WARRANT AGREEMENT, dated as of _________, 2003, between BioTime, Inc., a California corporation (the "Company"), and American Stock Transfer & Trust Company ("Warrant Agent") for the benefit of...Warrant Agreement • November 13th, 2003 • Biotime Inc • Biological products, (no disgnostic substances) • California
Warrant Agreement Dated as of March 27, 2002 WARRANT AGREEMENT, dated as of March 27, 2002, between BioTime, Inc., a California corporation (the "Company"), and Alfred D. Kingsley (the "Lender"). The Company proposes to issue a Common Share Purchase...Warrant Agreement • April 1st, 2002 • Biotime Inc • Biological products, (no disgnostic substances) • California
LINEAGE CELL THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt SecuritiesIndenture • March 11th, 2021 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Indenture, dated as of [●], 20__, among Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):
Lineage Cell Therapeutics, Inc. Common Shares (no par value per share) Sales AgreementSales Agreement • March 22nd, 2024 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Lineage Cell Therapeutics, Inc. and ________, as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of ______________Warrant Agreement • May 1st, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Debt Securities Warrant Agreement (this “Agreement”), dated as of ________ between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”) and _________, a [corporation] [national banking association] organized and existing under the laws of _________ and having a corporate trust office in _______, as warrant agent (the “Warrant Agent”).
AKZO NOBELExclusive License Agreement • February 16th, 2001 • Biotime Inc • Biological products, (no disgnostic substances)
This guaranty applies to the Agreement as in effect on the date of this guaranty and as the Agreement may be amended, modified, or supplemented in the future by BioTime, Inc., and Horus B.V. Akzo Nobel N.V. agrees that any supplement, modification, amendment, extension, renewal, acceleration or other change of one or more terms of the Agreement and the obligations of Horus B.V. or BioTime, Inc. under the Agreement shall not affect the enforceability or continuing effectiveness of this guaranty even if executed or implemented by BioTime, Inc. and Horus B.V. without notice to or the consent or approval of Akzo Nobel N.V.
W I T N E S S E T H:Employment Agreement • May 17th, 1999 • Biotime Inc • Biological products, (no disgnostic substances)
Exhibit (a) MONTGOMERY SECURITIES CUSTOMER AGREEMENT This agreement sets forth the terms and conditions pursuant to which we, Montgomery Securities, and our successors and assigns, will maintain your account for purchases and sales of "securities and...Customer Agreement • September 25th, 1997 • Biotime Inc • Biological products, (no disgnostic substances) • New York
Certificate No. Warrant to Purchase ------ [Insert number of Shares]Warrant Agreement • August 18th, 2000 • Biotime Inc • Biological products, (no disgnostic substances)
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY NOT BE EXERCISED, SOLD, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED EXCEPT UNDER AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE AND THE HOLDER SHALL HAVE DELIVERED AN OPINION OF COUNSEL ADDRESSED TO THE COMPANY TO SUCH EFFECT; PROVIDED, THAT SUCH OPINION SHALL BE IN FORM AND SUBSTANCE AND FROM COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.
ADDENDUM NO. 3 TO LEASE This is an Addendum to the Lease dated June 1, 1993 in which BioTime, Inc., a California corporation, is referred to as "Lessee." The following changes are hereby incorporated. In the event of a conflict of terms, those of this...Lease Addendum • March 31st, 1999 • Biotime Inc • Biological products, (no disgnostic substances)
EMPLOYMENT AGREEMENT THIS AGREEMENT is made April 1, 1997 by and between BioTime, Inc. (the "Company"), and Ronald S. Barkin, Esq. (the "Employee"). W I T N E S S E T H: WHEREAS, the Company desires to employ Employee, and Employee is willing to...Employment Agreement • May 15th, 1997 • Biotime Inc • Biological products, (no disgnostic substances) • California
REVOLVING LINE OF CREDIT AGREEMENT by and between BIOTIME, INC. as "Borrower"Revolving Line of Credit Agreement • April 1st, 2002 • Biotime Inc • Biological products, (no disgnostic substances) • California
9,615,385 Shares* BioTime, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 13th, 2017 • Biotime Inc • Biological products, (no disgnostic substances) • New York
BioTime, Inc., a California corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 9,615,385 shares of its Common Stock, no par value per share (the “Common Stock”). The aggregate of 9,615,385 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,442,308 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
LEASE by and between BMR-6300 DUMBARTON CIRCLE LP, a Delaware limited partnership and ASTERIAS BIOTHERAPEUTICS, INC., a Delaware corporationLease • March 17th, 2014 • Biotime Inc • Biological products, (no disgnostic substances)
Notwithstanding anything to the contrary in the above chart, during the first fifteen (15) months of the Term (and provided that Tenant is not then in default (beyond any applicable notice and cure periods) of any of its obligations under this Lease), Tenant’s Base Rent shall be calculated based upon twenty-two thousand (22,000) square feet of Rentable Area; provided, however, that Tenant shall have access to and use of the entire Premises subject to and in accordance with the terms and provisions of the Lease.
7,322,176 Shares BIOTIME, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 17th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • New York
BioTime, Inc., a California corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,322,176 shares (the “Firm Shares”) of the Company’s common stock, no par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,098,326 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over‑allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
LEASE AGREEMENT By and Between SKS HARBOR BAY ASSOCIATES, LLC, a Delaware limited liability company (“Landlord”) and BIOTIME, INC., a California corporation (“Tenant”) October 28, 2010Lease Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • California
Lineage Cell Therapeutics, Inc. and ________, as Warrant Agent Form of Preferred Share Warrant Agreement Dated as of ___________Warrant Agreement • May 1st, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Preferred Share Warrant Agreement (this “Agreement”), dated as of between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
Lineage Cell Therapeutics, Inc. and ________, As Warrant Agent Form of Common Share Warrant Agreement Dated as of _____________Common Share Warrant Agreement • March 11th, 2021 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Common Share Warrant Agreement (this “Agreement”), dated as of __________between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”) and _________, a [corporation] [national banking association] organized and existing under the laws of __________ and having a corporate trust office in ________ , as warrant agent (the “Warrant Agent”).
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • August 11th, 2022 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Indemnification Agreement (“Agreement”) is made as of ______, by and between Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), and __________(“Indemnitee”).
Warrant Agreement Dated as of January 14, 2013Warrant Agreement • March 18th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
WARRANT AGREEMENT, (this “Agreement”) dated as of January 14, 2013, by BioTime, Inc., a California corporation (the “Company”), for the benefit of each registered holder of a Warrant described herein (a “Holder”).
WARRANTWarrant Agreement • August 29th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • Delaware
NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS WARRANT IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORT
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 29th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Securities Purchase Agreement (this “Agreement”) is dated as of August 29, 2016, between OncoCyte Corporation, a California corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
STOCK OPTION AGREEMENTStock Option Agreement • March 14th, 2019 • Biotime Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT made and entered into effective as of September 17, 2018, by and between BioTime, Inc., a California corporation (the “Company”), and Brian M. Culley, an employee (the “Employee”) of the Company.
Exhibit 10.20 EXCLUSIVE LICENSE AGREEMENT Between BioTime, Inc. and CJ Corp. TABLE OF CONTENTSExclusive License Agreement • March 31st, 2003 • Biotime Inc • Biological products, (no disgnostic substances) • California
ASTERIAS BIOTHERAPEUTICS, INC. 384,615 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2015 • Biotime Inc • Biological products, (no disgnostic substances) • New York
Asterias Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this Underwriting Agreement (this “Agreement”), to issue and sell to MLV & Co. LLC (the “Underwriter”), an aggregate of 384,615 shares (the “Shares”) of the Company’s Series A common stock, par value $0.0001 per share (the “Common Stock”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
EMPLOYMENT AGREEMENT (“Agreement”) is made May 20, 2019 (“Effective Date”), by and between BioTime, Inc. (“Company”), a California corporation, and Chase C. Leavitt (“Executive”).
LICENSE AGREEMENTLicense Agreement • May 24th, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • Pennsylvania
This LICENSE AGREEMENT (the “Agreement”) is made as of the 22nd day of January, 2016 (the “Effective Date”), by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a nonprofit corporation organized and existing under the laws of the Commonwealth of Pennsylvania located at 3601 Spruce Street, Philadelphia, PA 19104 (“Wistar”), and ONCOCYTE CORPORATION, a corporation organized and existing under the laws of the State of California, with a principal place of business located at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“Company”).
PURCHASE AGREEMENT ASTERIAS BIOTHERAPEUTICS, INC. 1,000,000 BioTime Inc. Common Shares with 1,000,000 Asterias Series B Common Stock Purchase Warrants Total Purchase Price $2,500,000 READ THIS AGREEMENT CAREFULLY BEFORE YOU INVESTPurchase Agreement • August 11th, 2014 • Biotime Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement is entered into by Broadwood Partners, L.P. (“Purchaser”) and Asterias Biotherapeutics, Inc., a Delaware corporation (the “Company).
STOCK OPTION AGREEMENT (Director)Stock Option Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT made and entered into as of ______, 20___, by and between BioTime, Inc., a California corporation (the "Company"), and _________, a director (the "Optionee") of the Company or of a subsidiary of the Company (hereinafter included within the term "Company") within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the "Code"),
REVOLVING CREDIT NOTERevolving Credit Note • October 19th, 2007 • Biotime Inc • Biological products, (no disgnostic substances)
FOR VALUE RECEIVED, the undersigned, BioTime, Inc., a California corporation (Borrower") hereby promises to pay to the order of ___________("Lender") the principal sum of _____________ DOLLARS ($_______________) or such lesser amount as may from time to time be outstanding as the Loan pursuant to that certain First Amended and Restated Revolving Line of Credit Agreement, dated October 17, 2007, between Borrower and Lender (the "Credit Agreement"), together with interest on the unpaid balance of the Loan at the rate or rates hereinafter set forth. This Revolving Credit Note is one of the Notes described in the Credit Agreement. All capitalized terms not otherwise defined in this Note shall have the meanings defined in the Credit Agreement.
EXHIBIT 10.19 STAND-BY PURCHASE AGREEMENTStand-by Purchase Agreement • October 3rd, 2003 • Biotime Inc • Biological products, (no disgnostic substances) • California
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 9th, 2015 • Biotime Inc • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of September 14, 2015 (the “Effective Date”) by and between BioTime, Inc., a California corporation (the “Company”) and the undersigned identified on the signature page attached hereto (“Purchaser”).
PARTICIPATING DEBENTURE HOLDERS:Stand-by Purchase Agreement • December 5th, 2003 • Biotime Inc • Biological products, (no disgnostic substances)
BioTime, Inc., a California corporation (the "Company"), each of the undersigned Participating Debenture Holders have entered into a Standby Purchase Agreement, dated October 2, 2003 (the "Agreement"). Unless otherwise defined, capitalized terms used in this Amendment have the same meaning ascribed in the Agreement. The Company has filed the Registration Statement contemplated by the Agreement. The staff of the Securities and Exchange Commission has advised the Company that they are unable to determine that Milton Dresner would be acting within the safe harbor from registration as a broker-dealer under Rule 3a4-1. Accordingly, the parties agree to that Milton Dresner hereby withdraws as a Participating Debenture Holder, and Schedule I of the Agreement is amended as attached.
CROSS LICENSE AGREEMENT between ASTERIAS and BIOTIME and ESICross License Agreement • February 22nd, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • Delaware
This CROSS-LICENSE AGREEMENT (the “Agreement”) is entered into on February 16, 2016 (the “Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation, having a place of business at 6300 Dumbarton Circle, Fremont, CA 94555 (“Asterias”), BioTime, Inc., a California corporation, having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“BioTime”), and ES Cell International Pte Ltd., a corporation wholly owned by BioTime organized under the laws of Singapore and having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“ESI”) (each individually referred to as “Party” and collectively as the “Parties”).
